Healthcare

Clarity Pharmaceuticals (ASX:CU6) is a clinical-stage developer rather than a commercial manufacturer of approved cancer medicines. Its technology pairs copper-64 for positron emission tomography imaging with copper-67 for targeted radiation treatment. The SAR-bisPSMA program focuses on prostate cancer, including diagnostic imaging and treatment of …

PolyNovo's product range centres on NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. BTM is a synthetic matrix designed to support dermal reconstruction before definitive wound closure. MTX is a complementary dermal scaffold used in managing tissue deficits. Product selection and applications depend on …

Cogstate (ASX:CGS) supplies computerized tests designed to measure memory, attention and other aspects of cognition. Its clinical trial work includes digital assessment, remote testing, scientific consulting, rater training and centralized monitoring of assessment quality. Sponsors use these services to evaluate cognitive endpoints in neurological, …

The company collects and analyses clinical samples for routine and specialised diagnostics. Its services span chemical pathology, haematology, microbiology, histopathology, genetic screening, molecular cancer testing and clinical trials. The group also undertakes veterinary and occupational testing. Australian Clinical Labs (ASX:ACL) operates a network of …

The Minnesota-based medical technology company supplies equipment, mapping software and disposable instruments used inside interventional magnetic resonance (iMR) laboratories. Its portfolio includes the NorthStar mapping and guidance system, Vision-MR diagnostic and ablation catheters, and Advantage-MR electrophysiology recording equipment. Imricor (ASX:IMR) has activities in Europe …

Artrya Limited (ASX:AYA) develops and commercialises Salix, a software platform that helps clinicians review coronary computed tomography angiography (CCTA) studies. Its tools visualise coronary anatomy and plaque characteristics to support assessment of coronary artery disease. The software is an adjunct to, rather than a …

Following quarter end, Starpharma submitted its Clinical Trial Application through the European Union Clinical Trials Information System for approval to run the first-in-human Phase 1 study in the Netherlands. During the quarter it completed manufacture of the non-radiolabelled DEP® HER2-Lu clinical material and advanced …